Quidel Stock Hits New 52-Week High (QDEL)

NEW YORK ( TheStreet) -- Quidel Corporation (Nasdaq: QDEL) hit a new 52-week high Tuesday as it is currently trading at $19.14, above its previous 52-week high of $19.09 with 60,611 shares traded as of 12:29 p.m. ET. Average volume has been 155,000 shares over the past 30 days.

Quidel has a market cap of $497.5 million and is part of the health care sector and drugs industry. Shares are up 24.9% year to date as of the close of trading on Monday.

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, women's health, and gastrointestinal diseases. The company has a P/E ratio of 79.9, above the average drugs industry P/E ratio of 74.9 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Quidel as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full Quidel Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Abbott CEO: Another Alere-Related Divestiture Coming Soon

Alere, St. Jude Deals in Focus as Abbott Releases Q2 Earnings

Quidel Diversifies With Alere's Triage Assets

Action Was Under the Surface in Monday's Market

Insider Trading Alert - QDEL, SPRT And SJW Traded By Insiders